Literature DB >> 29215629

Proton Pump Inhibitors and Dementia: Deciphering the Data.

Paul Moayyedi1, Maxine A Lewis2.   

Abstract

Proton pump inhibitors (PPIs) are effective and suppressing acid, and therefore have efficacy against gastric acid-related disorders. The long-term safety of PPIs is less clear and there have been a number of studies raising concerns regarding risk of pneumonia, fracture, Clostridium difficile, chronic renal failure, and dementia. This latter concern is addressed by a study in this issue of AJG using health care registry data and found there was no association between PPI use and Alzheimer's dementia. Furthermore, there was no increased risk of dementia with long-term use of PPIs or higher doses of PPIs. Discrepancies between studies probably relate to multiple testing and residual confounding and currently there is insufficient evidence to suggest that the association between PPIs and dementia is causal.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29215629     DOI: 10.1038/ajg.2017.415

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  19 in total

1.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 2.  The risks of PPI therapy.

Authors:  Paul Moayyedi; Grigorios I Leontiadis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-14       Impact factor: 46.802

Review 3.  Gastro-oesophageal reflux disease.

Authors:  Paul Moayyedi; Nicholas J Talley
Journal:  Lancet       Date:  2006-06-24       Impact factor: 79.321

4.  Hip fracture and proton pump inhibitor therapy: position statement.

Authors:  Paul Moayyedi
Journal:  Can J Gastroenterol       Date:  2008-10       Impact factor: 3.522

5.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

Review 6.  Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.

Authors:  Jackie Bosch; John W Eikelboom; Stuart J Connolly; Nancy Cook Bruns; Vivian Lanius; Fei Yuan; Frank Misselwitz; Edmond Chen; Rafael Diaz; Marco Alings; Eva M Lonn; Petr Widimsky; Masatsugu Hori; Alvaro Avezum; Leopoldo S Piegas; Deepak L Bhatt; Kelley R H Branch; Jeffrey L Probstfield; Yan Liang; Lisheng Liu; Jun Zhu; Aldo P Maggioni; Patricio Lopez-Jaramillo; Martin O'Donnell; Keith A A Fox; Ajay Kakkar; Alexander N Parkhomenko; Georg Ertl; Stefan Störk; Katalin Keltai; Matyas Keltai; Lars Ryden; Gilles R Dagenais; Nana Pogosova; Antonio L Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomasz J Guzik; Peter B Verhamme; Dragos Vinereanu; Jae-Hyung Kim; Jong-Won Ha; Andrew M Tonkin; John D Varigos; Basil S Lewis; Camilo Felix; Khalid Yusoff; Philippe Gabriel Steg; Victor Aboyans; Kaj P Metsarinne; Sonia S Anand; Robert G Hart; Andre Lamy; Paul Moayyedi; Darryl P Leong; Mukul Sharma; Salim Yusuf
Journal:  Can J Cardiol       Date:  2017-06-08       Impact factor: 5.223

7.  Risk of dementia in elderly patients with the use of proton pump inhibitors.

Authors:  Britta Haenisch; Klaus von Holt; Birgitt Wiese; Jana Prokein; Carolin Lange; Annette Ernst; Christian Brettschneider; Hans-Helmut König; Jochen Werle; Siegfried Weyerer; Melanie Luppa; Steffi G Riedel-Heller; Angela Fuchs; Michael Pentzek; Dagmar Weeg; Horst Bickel; Karl Broich; Frank Jessen; Wolfgang Maier; Martin Scherer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-10-24       Impact factor: 5.270

8.  Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.

Authors:  Willy Gomm; Klaus von Holt; Friederike Thomé; Karl Broich; Wolfgang Maier; Anne Fink; Gabriele Doblhammer; Britta Haenisch
Journal:  JAMA Neurol       Date:  2016-04       Impact factor: 18.302

9.  Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.

Authors:  Nigam H Shah; Paea LePendu; Anna Bauer-Mehren; Yohannes T Ghebremariam; Srinivasan V Iyer; Jake Marcus; Kevin T Nead; John P Cooke; Nicholas J Leeper
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

10.  The proton-pump inhibitor lansoprazole enhances amyloid beta production.

Authors:  Nahuai Badiola; Victor Alcalde; Albert Pujol; Lisa-Marie Münter; Gerd Multhaup; Alberto Lleó; Mireia Coma; Montserrat Soler-López; Patrick Aloy
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

View more
  3 in total

1.  No association between proton pump inhibitor use and ALS risk: a nationwide nested case-control study.

Authors:  Hakan Cetin; Jiangwei Sun; Catarina Almqvist; Berthold Reichardt; Matthias Tomschik; Fritz Zimprich; Fang Fang; Caroline Ingre
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

2.  Increased risk of death associated with the use of proton-pump inhibitors in patients with dementia and controls - a pharmacoepidemiological claims data analysis.

Authors:  H Cetin; R Wurm; B Reichardt; M Tomschik; S Silvaieh; T Parvizi; T König; A Erber; E Schernhammer; T Stamm; E Stögmann
Journal:  Eur J Neurol       Date:  2020-05-06       Impact factor: 6.089

3.  The Janus-like Association between Proton Pump Inhibitors and Dementia.

Authors:  Anna Papazoglou; Muhammad I Arshaad; Christina Henseler; Johanna Daubner; Karl Broich; Britta Haenisch; Marco Weiergräber
Journal:  Curr Alzheimer Res       Date:  2021       Impact factor: 3.498

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.